December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Suppression of Diabetic Retinopathy with Angiopoietin-1
Author Affiliations & Notes
  • AP Adamis
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • V Poulaki
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • T Qaum
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • Q Xu
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • Y Moromizato
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • S-E Bursell
    Ophthalmology Joslin Diabetes Center Boston MA
  • SJ Wiegand
    Neuroendocrine & Obesity Research
    Regeneron Pharmaceuticals Tarrytown NY
  • J Rudge
    Regeneron Pharmaceuticals Tarrytown NY
  • G Yancopoulos
    Regeneron Pharmaceuticals Tarrytown NY
  • A Joussen
    Ophthalmology MEEI/Harvard Medical School Boston MA
  • Footnotes
    Commercial Relationships    A.P. Adamis, Regeneron Pharmaceuticals F, C; V. Poulaki, None; T. Qaum, None; Q. Xu, None; Y. Moromizato, None; S. Bursell, None; S.J. Wiegand, Regeneron Pharmaceuticals E; J. Rudge, Regeneron Pharmaceuticals E; G. Yancopoulos, Regeneron Pharmaceuticals E; A. Joussen, None. Grant Identification: NIH, JDF, DFG, Lions, Iaccoca and Falk Foundations
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2965. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      AP Adamis, V Poulaki, T Qaum, Q Xu, Y Moromizato, S-E Bursell, SJ Wiegand, J Rudge, G Yancopoulos, A Joussen; Suppression of Diabetic Retinopathy with Angiopoietin-1 . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2965.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:A critical early pathology in diabetic retinopathy is the adhesion of leukocytes to the retinal vasculature, a process that occurs, in part, via intercellular adhesion molecule-1 (ICAM-1). Recent findings with angiopoietin-1 suggested that it might be worth evaluating in models of diabetic retinopathy. Methods: Diabetes was induced with streptozotocin in mice and rats. Angiopoietin-1 was delivered locally via intravitreous injection (rats) or systemically via an adenovirus (mice). Retinal leukostasis, blood-retinal barrier breakdown and endothelial cell injury were quantified. Retinal VEGF and ICAM-1 levels were assessed, as were retinal levels for eNOS, nitric oxide, Akt and MAP kinase activity. Retinal VEGF bioactivity was inhibited with a soluble Flt-1/Fc chimera. Results: Angiopoietin-1 prevented and reversed many of the diabetic retinal vascular changes associated with both new and established diabetes. Specifically, angiopoietin-1 normalized retinal vascular endothelial growth factor (VEGF) and ICAM-1 mRNA and protein levels, leading to reductions in leukocyte adhesion, endothelial cell injury and blood-retinal barrier breakdown. These changes coincided with reductions in retinal eNOS, nitric oxide and Akt and MAP kinase activity, known mediators of VEGF bioactivity and leukocyte adhesion. When endogenous VEGF bioactivity was specifically inhibited with a soluble Flt-1/Fc chimera, retinal Akt kinase activity was significantly reduced in vivo. Conclusion: These data identify new vascular and anti-inflammatory bioactivities for angiopoietin-1. They also highlight angiopoietin-1 as the first known naturally occurring protein that directly protects the retinal vasculature in diabetes.

Keywords: 388 diabetic retinopathy • 339 cell adhesions/cell junctions • 423 growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×